Development and Characterization of Nanoparticles for the Delivery of Gemcitabine Hydrochloride

Gemcitabine (2,2-difluorodeoxycytidine) is a deoxycytidine analog, currently being used as a first-choice drug in pancreatic metastatic cancer. Gemcitabine is administered weekly as 30-minute infusion with starting dose ranging from 800 to 1250 mg/m2. The aim of the present work was to develop starc...

Full description

Saved in:
Bibliographic Details
Published in:TheScientificWorld 2014-01, Vol.2014 (2014), p.1-6
Main Authors: Khaira, Rekha, Saini, Vinay, Sharma, Jyoti
Format: Article
Language:English
Subjects:
Cancer therapies
Cell Line, Tumor
Chemical synthesis
Deoxycytidine - analogs & derivatives
Deoxycytidine - chemistry
Deoxycytidine - pharmacology
Dosage and administration
Drug Carriers - chemistry
Drug Carriers - pharmacology
Drug delivery systems
Drugs
Gemcitabine
Hepatocytes - drug effects
Humans
Inhibitory Concentration 50
Medical prognosis
Methods
Molecular weight
Nanoparticles
Nanoparticles - chemistry
Pancreas
Pancreatic cancer
Particle size
Production processes
Retention time
Side effects
Starch - chemistry
Studies
Technology application
Vehicles
Zeta potential
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gemcitabine (2,2-difluorodeoxycytidine) is a deoxycytidine analog, currently being used as a first-choice drug in pancreatic metastatic cancer. Gemcitabine is administered weekly as 30-minute infusion with starting dose ranging from 800 to 1250 mg/m2. The aim of the present work was to develop starch nanoparticles (NPs) for the delivery of gemcitabine hydrochloride that could reduce its dose related side effects and may prolong its retention time (24 hrs) for the treatment of pancreatic cancer. Nanoparticles were prepared by emulsification diffusion method with slight modifications. Size and morphology of nanoparticles were investigated. Particles were spherical in shape with slightly rough surfaces. Particle size and polydispersity index were 231.4 nm and 1.0, respectively while zeta potential of blank NPs and drug loaded NPs were found to be −11.8 mV and −9.55 mV, respectively. Percent entrapment efficiency of different formulations was around ∼54% to 65%. In vitro release profile studies showed that around 70%–83% of drug was released from different formulations. Anticancerous cell line studies were also performed in human pancreatic cell lines (MIA-PA-CA-2).
ISSN:2356-6140
1537-744X
1537-744X
DOI:10.1155/2014/560962